The substantia nigra is the main target, but Parkinson's spreads beyond it
Parkinson's disease primarily damages a small region deep in the brain called the substantia nigra, which sits in the midbrain just above the brainstem. This area produces dopamine, a chemical messenger that coordinates movement. When Parkinson's destroys these dopamine-producing cells, the brain loses the signals it needs to control smooth, intentional motion — which is why tremor, stiffness, and slowness are the hallmark signs.
But Parkinson's does not stop at the substantia nigra. As the disease progresses, it damages other brain regions that also rely on dopamine or contain the same toxic protein clumps that mark the disease. This spreading damage explains why Parkinson's eventually affects mood, memory, sleep, and thinking — not just movement.
Understanding which brain areas are involved helps explain why your symptoms change over time and why different medications and treatments target different problems. It also shows why one person's Parkinson's looks different from another's.
Key Takeaways
- The substantia nigra, a dopamine-producing region deep in the brain, is the primary target of Parkinson's disease.
- Loss of dopamine in the substantia nigra causes the movement problems — tremor, rigidity, and slowness — that define Parkinson's.
- Parkinson's also damages the locus coeruleus, which produces norepinephrine and affects mood, attention, and blood pressure control.
- As Parkinson's spreads to the cortex and other regions, it can cause cognitive changes, depression, and sleep disturbances.
- Levodopa and other dopamine-replacement drugs work because they restore the chemical the substantia nigra no longer makes.
How dopamine loss in the substantia nigra causes movement problems
The substantia nigra sits in a region called the basal ganglia, which acts as the brain's movement control center. Dopamine-producing neurons in the substantia nigra send signals to other parts of the basal ganglia that tell your muscles when to move, how fast, and how smoothly. When Parkinson's destroys 50 to 60 percent of these neurons, the basal ganglia stop receiving enough dopamine to function normally.
Without adequate dopamine, the basal ganglia cannot properly filter and refine movement commands. This creates the four cardinal signs of Parkinson's: resting tremor (shaking at rest), rigidity (stiffness), bradykinesia (slowness of movement), and postural instability (balance problems). The tremor often starts in one hand and spreads. The stiffness feels like your limbs are moving through resistance. The slowness makes everyday tasks like buttoning a shirt or walking take much longer.
This is why levodopa and dopamine agonists — the main Parkinson's medications — work: they restore dopamine to the basal ganglia and improve movement control. However, as more neurons die over years, medications become less effective because there are fewer cells left to convert the medication into usable dopamine.
The locus coeruleus and non-movement symptoms
The locus coeruleus is a small cluster of neurons in the brainstem that produces norepinephrine, a chemical that affects mood, attention, blood pressure, and sleep. Parkinson's damages this region early in the disease, often before or alongside the substantia nigra damage. This explains why many people with Parkinson's experience depression, anxiety, and sleep problems years before movement symptoms appear.
Norepinephrine loss also contributes to orthostatic hypotension — a sudden drop in blood pressure when you stand up — which is common in Parkinson's and can cause dizziness or fainting. It also affects attention and the ability to focus, which some people notice before they notice tremor or stiffness.
Because the locus coeruleus damage happens early and independently, treating movement symptoms alone does not address these non-movement problems. This is why doctors often prescribe separate medications for depression or blood pressure control alongside dopamine-replacement drugs.
Spread to the cortex and cognitive changes
In later stages, Parkinson's spreads to the cortex — the outer layer of the brain responsible for thinking, memory, and judgment. This progression explains why some people develop cognitive changes, including slowed thinking, difficulty with complex tasks, or in advanced cases, dementia. The spread is not inevitable or uniform; some people maintain sharp thinking throughout their lives, while others experience cognitive decline.
The cortex also controls executive function — planning, organizing, and decision-making. Damage here can make it harder to multitask or switch between activities. Some people notice they can no longer do two things at once, such as walking while talking, without losing balance or forgetting what they were saying.
Levodopa and other dopamine drugs do not reach the cortex as effectively as they reach the basal ganglia, which is one reason cognitive symptoms are harder to treat than movement symptoms. Cognitive changes may respond better to other approaches, such as cognitive rehabilitation or treatment of depression and sleep problems, which can worsen thinking.
Other brain regions affected as Parkinson's progresses
Beyond the substantia nigra, locus coeruleus, and cortex, Parkinson's can damage the nucleus basalis of Meynert (which produces acetylcholine and affects memory and attention), the raphe nuclei (which produce serotonin and affect mood and pain), and the hypothalamus (which controls sleep, temperature, and hormone balance). This widespread damage explains the full range of Parkinson's symptoms.
The pattern of spread varies from person to person. Some people's disease progresses mainly in movement-related regions and causes few cognitive or mood changes. Others experience significant non-movement symptoms early. Researchers are still working to understand why the pattern differs and whether it can be predicted from early symptoms.
This variation is also why Parkinson's affects people so differently. Two people diagnosed on the same day may have entirely different symptom profiles and treatment needs based on which brain regions their disease has already damaged.
Why brain imaging does not always show Parkinson's damage
A standard MRI or CT scan of the brain usually looks normal in Parkinson's disease, even though significant dopamine loss has occurred. This is because the damage is chemical and cellular — the death of dopamine-producing neurons — not structural. The brain tissue itself does not shrink or show obvious lesions in early to middle stages.
Specialized imaging called PET scans or SPECT scans can detect dopamine loss by measuring how much dopamine the brain is producing, but these tests are expensive and not routinely used for diagnosis. Doctors diagnose Parkinson's based on your symptoms and how you respond to levodopa, not on imaging.
In advanced Parkinson's, an MRI may show some brain shrinkage or changes, but these are not specific to Parkinson's and do not confirm the diagnosis. This is why your doctor's clinical assessment — watching how you move, checking your reflexes, and observing your response to medication — remains the gold standard for diagnosis.
What happens to the brain over time
Parkinson's is a progressive disease, meaning the damage accumulates over years or decades. The rate of progression varies widely. Some people have mild symptoms for 10 or 15 years; others progress more quickly. The initial rate of dopamine loss does not always predict how fast symptoms will worsen later.
As more dopamine neurons die, the brain's remaining neurons work harder to compensate. This is why symptoms may stay stable for a while, then suddenly worsen — the brain has exhausted its ability to compensate. It is also why medication doses often need to increase over time: the brain has fewer dopamine-producing cells left to work with.
Research into why Parkinson's spreads and how to slow or stop the damage is ongoing. Current medications treat symptoms by replacing dopamine or making the remaining dopamine work more efficiently, but they do not stop the underlying cell death. Understanding the brain regions involved helps researchers design future treatments that might slow or prevent progression.
Frequently Asked Questions
Can Parkinson's damage be seen on an MRI?
Standard MRI scans usually appear normal in Parkinson's because the disease damages cells at a chemical level, not the brain's structure. Specialized PET or SPECT scans can detect dopamine loss, but these are expensive and not used routinely for diagnosis. Doctors diagnose Parkinson's based on symptoms and medication response, not imaging.
Why do some people with Parkinson's have depression or anxiety before movement symptoms?
Parkinson's often damages the locus coeruleus, which produces norepinephrine and affects mood, before or alongside damage to the substantia nigra. This is why depression, anxiety, and sleep problems can appear years before tremor or stiffness. Treating these symptoms separately from movement problems is important.
Does Parkinson's always affect thinking and memory?
No. Parkinson's spreads to the cortex at different rates in different people. Some people maintain sharp thinking throughout their lives, while others develop cognitive changes in later stages. The pattern is unpredictable and varies widely from person to person.
Why do Parkinson's medications stop working as well over time?
As Parkinson's kills more dopamine-producing neurons, there are fewer cells left to convert medication into usable dopamine. The brain's ability to compensate also decreases. This is why doses often need to increase and why medication timing becomes more important as the disease progresses.
Is the damage from Parkinson's reversible?
Current medications do not reverse dopamine cell death; they replace the dopamine those cells no longer make or help remaining cells work more efficiently. Research into treatments that might slow or stop cell death is ongoing, but no cure exists yet.